But Tercica has orphan status for its drug, which should protect Increlex from competition for seven years.

FORBES

Insmed, another biotech that is developing a similar drug, had filed a petition with the FDA regarding Increlex's safety profile.

FORBES

The Food and Drug Administration has approved Increlex, a medicine developed by biotech Tercica to treat a hormone deficiency that causes short stature and other health problems for 6, 000 children.

FORBES